Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK1 S646P |
Therapy | Ruxolitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK1 S646P | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Jakafi (ruxolitinib) resulted in inhibition of both Jak1 autophosphorylation and Stat3 and Erk activity, and inhibition of cell proliferation in culture in transformed cells expressing JAK1 S646P (PMID: 28410228). | 28410228 |
PubMed Id | Reference Title | Details |
---|---|---|
(28410228) | Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia. | Full reference... |